Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

Vikram Karnani Biography and Net Worth

EVP of Horizon Therapeutics Public

Vikram Karnani joined Horizon in July 2014. Before joining Horizon, Karnani was with Fresenius Kabi, a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, where he served as vice president of the therapeutics and cell therapy business, with a focus on sales, marketing and clinical implementation. He also held various positions in business development, corporate strategy and strategic marketing within Fenwal Inc., a private equity owned global medical device company, that was acquired by Fresenius Kabi.

Karnani brings more than 15 years of cross functional expertise across a multitude of industries, including medical devices, management consulting, semiconductors and cellular telecommunications.

Karnani has a Master of Business Administration from the Kellogg School of Management at Northwestern University, a master's degree in electrical engineering from Case Western Reserve University and a bachelor's degree in electrical engineering from University of Bombay, India.

What is Vikram Karnani's net worth?: The estimated net worth of Vikram Karnani is at least $12.19 million as of February 22nd, 2021. Karnani owns 104,810 shares of Horizon Therapeutics Public stock worth more than $12,189,403 as of November 15th. This net worth evaluation does not reflect any other investments that Karnani may own. Learn More about Vikram Karnani's net worth.
How do I contact Vikram Karnani?: The corporate mailing address for Karnani and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Vikram Karnani's contact information.
Has Vikram Karnani been buying or selling shares of Horizon Therapeutics Public?: Vikram Karnani has not been actively trading shares of Horizon Therapeutics Public within the last three months. Most recently, Vikram Karnani sold 8,358 shares of the business's stock in a transaction on Monday, February 22nd. The shares were sold at an average price of $87.19, for a transaction totalling $728,734.02. Following the completion of the sale, the executive vice president now directly owns 104,810 shares of the company's stock, valued at $9,138,383.90. Learn More on Vikram Karnani's trading history.
Who are Horizon Therapeutics Public's active insiders?: Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Vikram Karnani Insider Trading History at Horizon Therapeutics Public

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/22/2021	Sell	8,358	$87.19	$728,734.02	104,810
1/22/2021	Sell	2,731	$76.81	$209,768.11	116,333
6/1/2020	Sell	2,369	$50.23	$118,994.87
1/6/2020	Sell	9,297	$35.62	$331,159.14	92,654
7/1/2019	Sell	13,111	$25.02	$328,037.22

Vikram Karnani Buying and Selling Activity at Horizon Therapeutics Public

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: $116.30

$116.30

50 Day Range

MA: $115.72

$112.60

$116.30

2 Week Range

Now: $116.30

$60.03

$116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03